Genscript Biotech マネジメント

マネジメント基準チェック /24

Genscript Biotechの CEO はWeihui Shaoで、 Jul2021年に任命され、の在任期間は 3.33年です。の年間総報酬は$ 2.48Mで、 14.3%給与と85.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.034%を直接所有しており、その価値は€ 927.93K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と1.7年です。

主要情報

Weihui Shao

最高経営責任者

US$2.5m

報酬総額

CEO給与比率	14.3%
CEO在任期間	3.3yrs
CEOの所有権	0.03%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	1.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Genscript Biotech の収益と比較して、Weihui Shao の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

報酬と市場: Weihuiの総報酬 ($USD 2.48M ) は、 German市場 ($USD 1.97M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Weihuiの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Weihui Shao (44 yo)

3.3yrs

在職期間

US$2,477,000

報酬

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Weihui Shao	CEO & COO	3.3yrs	US$2.48m	0.034% € 927.9k
Ye Wang	Co-Founder	22.8yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	no data	データなし	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	1.9yrs	US$531.00k	データなし
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Shiniu Wei	Chief Financial Officer	3.9yrs	データなし	データなし
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	no data	データなし	データなし

3.6yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: G51の経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Ye Wang	Co-Founder	9.5yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	9.5yrs	データなし	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	2.5yrs	US$531.00k	データなし
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Carl June	Member of Advisory Board	less than a year	データなし	データなし
George Church	Member of Advisory Board	5.2yrs	データなし	データなし
Alphonse Galdes	Independent Non-Executive Director	less than a year	データなし	データなし
David Liu	Member of Scientific Advisory Board	less than a year	データなし	データなし
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	データなし	データなし
Chenyang Shi	Independent Non-Executive Director	less than a year	データなし	データなし
Ethan Pan	Independent Non-Executive Director	less than a year	データなし	データなし

1.7yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: G51の取締役会は経験豊富ではない ( 1.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Genscript Biotech マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

New major risk - Share price stability

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Now 22% undervalued after recent price drop

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 22% undervalued after recent price drop

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

New major risk - Share price stability

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

New minor risk - Share price stability

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold €159k worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Now 20% undervalued

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold €246k worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold €988k worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: €1.40

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: €1.06

New 90-day low: €1.08

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: €1.25

Co-Founder recently bought €410k worth of stock

First half earnings released

New 90-day low: €1.28

First half earnings released

New 90-day low - €1.60

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

New 90-day low - €1.66

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

マネジメント基準チェック /24